Peptide receptor radionuclide therapy (PRRT) of neuroendocrine tumors with somatostatin analogues

Research output: Contribution to journalArticlepeer-review


Background: Clinical experience with the radiolabeled somatostatin analogues 90Y-DOTATOC and, more recently, 177Lu-DOTATATE, is ongoing since more than a decade in few centers. Dosimetric studies demonstrated that 90Y-DOTATOC and 177Lu-DOTATATE are able to deliver high doses to somatostatin receptor sst2-expressing tumors and low doses to normal organs. Results and Conclusions: Clinical studies demonstrated that partial and complete objective responses in up to 30% of patients can be obtained, with a great survival benefit in treated patients. Side effects may involve the kidney and the bone marrow and are usually mild. Renal protection is used to minimize the risk of a late decrease of renal function.

Original languageEnglish
Pages (from-to)347-351
Number of pages5
JournalEuropean Review for Medical and Pharmacological Sciences
Issue number4
Publication statusPublished - Apr 2010


  • PRRT

ASJC Scopus subject areas

  • Medicine(all)
  • Pharmacology (medical)


Dive into the research topics of 'Peptide receptor radionuclide therapy (PRRT) of neuroendocrine tumors with somatostatin analogues'. Together they form a unique fingerprint.

Cite this